AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.

$6.68  -0.22 (-3.19%)
As of 07/26/2021 09:45:22 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  The Netherlands
IPO date:  09/12/2014
Outstanding shares:  98,287,333
Average volume:  1,401,414
Market cap:   $651,645,018
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N01045108
ISIN:        NL0010872420
Sedol:      BQQF5R2
Valuation   (See tab for details)
PE ratio:   -21.42
PB ratio:   4.86
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy